Chuck Jaffee of Marketwatch calls it the stupid investment of the week, noting that cutting the health care sector up into narrow pieces may not guarantee much of a return (http://www.marketwatch.com/news/story/dicing-health-sector-so-small/story.aspx?guid=%7B720D8969-E3BF-4AEE-B1CF-32FE47E8A1F6%7D). He compares it to the Pauze Tombstone fund, which invested in "death-services" and didn't do well. One of his issues is that some companies are competitors, so good news for one may not be good news for another. However, as demonstrated by CEGE's tie to DNDN when Dendreon was awaiting approval, good news for a competitor can also lift the value of all stocks in that category. Another issue is the expense. 0.75% for an index offering is high. Not mentioned in this article, but mentioned elsewhere is that the ETF is equally weighted, meaning that no stock is more than 15% of the ETF (http://biz.yahoo.com/seekingalpha/070416/30069_id.html?.v=1) Jaffee recommends the broader-based ETF, the HealthShares Composite (HHQ). But I still like this one because of the potential of one stock hitting it big. We will see dramatic improvements in cancer treatments in the next 10 years, and one of these stocks is bound to hit it big. Let's hope that the fund grows as more companies come out with solutions.

safe and an up play because of the nature of cancer

HealthShares Emerging Cancer (nyse: HHJ)

Inception: Jan. 23, 2007

Expense ratio: 0.75

Invests in emerging companies in cancer treatment.